Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for StageZero Life Sciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.36.
Current Consensus is
The current consensus among 1 investment analysts is to hold stock in StageZero Life Sciences.